As of June 9th, RudaCure Inc. was recognized for its technological and innovative excellence and selected for the 中小企业部' Big3 Innovation Sector 初创企业 Package Support Project. The company will receive KRW 300 million annually over three years for 研发 and commercialization activities related to GMP finished 制药 production and stability evaluation of RCI001, domestic Phase 1 临床试验, and FDA Phase 2 临床试验. Additionally, the company was selected for project support linked to the 中小企业部, qualifying for a maximum of KRW 13 billion in financial support.